WO2003074023A1 - Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect - Google Patents

Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect Download PDF

Info

Publication number
WO2003074023A1
WO2003074023A1 PCT/EP2003/001962 EP0301962W WO03074023A1 WO 2003074023 A1 WO2003074023 A1 WO 2003074023A1 EP 0301962 W EP0301962 W EP 0301962W WO 03074023 A1 WO03074023 A1 WO 03074023A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
formulation according
aerosol
hfa
medicament
Prior art date
Application number
PCT/EP2003/001962
Other languages
French (fr)
Inventor
Rebecca Jaine Davies
David Ganderton
David Andrew Lewis
Brian John Meakin
Gaetano Brambilla
Alessandra Ferraris
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200401006A priority Critical patent/EA008571B1/en
Priority to AU2003215597A priority patent/AU2003215597B2/en
Priority to BR0303348-1A priority patent/BR0303348A/en
Priority to IL16384203A priority patent/IL163842A0/en
Priority to JP2003572543A priority patent/JP2005519094A/en
Priority to US10/505,679 priority patent/US20050129621A1/en
Priority to AT03743339T priority patent/ATE488224T1/en
Priority to DE60334973T priority patent/DE60334973D1/en
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Priority to EP03743339A priority patent/EP1480616B1/en
Priority to KR10-2004-7012649A priority patent/KR20040091050A/en
Priority to NZ535019A priority patent/NZ535019A/en
Priority to CA2477879A priority patent/CA2477879C/en
Priority to MXPA04008370A priority patent/MXPA04008370A/en
Publication of WO2003074023A1 publication Critical patent/WO2003074023A1/en
Priority to NO20034874A priority patent/NO20034874L/en
Priority to TNP2004000148A priority patent/TNSN04148A1/en
Priority to HRP20040751 priority patent/HRP20040751A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Definitions

  • This invention relates to aerosol solution formulations comprising a medicament, a propellant, one or more co-solvents and optionally other additives commonly used in this kind of formulations.
  • compositions could be administered to the respiratory tract by using pressurised metered dose inhalers (pMDIs).
  • PMDIs use a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol.
  • the formulation can be a solution or a suspension.
  • Solution formulations in comparison to suspensions, do not present problems of physical stability of the suspended particles and could therefore guarantee a higher dose uniformity and reproducibility.
  • hydrofluoroalkanes known also as hydro-fluoro-carbons (HFCs)
  • HFCs hydro-fluoro-carbons
  • CFCs Freons
  • HFA 134a 1,1,1,2-tetrafluoroethane
  • HFA 2207 1,1,1,2,3,3,3- heptafluoropropane
  • the aim of providing solution formulations in a HFA propellant for aerosol delivery of medicaments is to give a prompt systemically active dose of said medicament via the respiratory tract.
  • medicament is used to define any pharmaceutical active compound which could take advantage from a pulmonary delivery so as to produce a systemic therapeutic effect.
  • An important parameter for an efficient aerosol delivery to produce a systemic therapeutic effect is the particle size distribution in the aerosol cloud.
  • the particle size of the cloud is dominated by the particle size of the suspended drug, defined by the milling/micronization process.
  • the volumetric contribution of suspended drug particles is absent and much finer liquid droplets clouds, largely defined by the drug concentration in the solution, are generated.
  • the size of the particles provided by the pMDI is normally expressed as mass median aerodynamic diameter (MMAD).
  • MMAD mass median aerodynamic diameter
  • the particle size of choice of aerosol medicaments for the treatment of bronchopulmonary diseases is usually of approximately 3 ⁇ m.
  • the preferred diameter of the aerosol particles or droplets is comprised between 0.5 and 5 ⁇ m.
  • the particles should be small enough to be delivered to the lungs and to be absorbed into the bloodstream upon inhalation, i.e. of a size advantageously comprised between about 0.5 ⁇ m and 2.5 ⁇ m (MMAD of about 1-2 ⁇ m). Particles smaller than 0.5 ⁇ m are indeed not therapeutically useful as they are exhaled.
  • aerosol solution formulations offer the advantage of being homogeneous with the active ingredient and with the excipients which are completely dissolved in the propellant vehicle or in the mixtures thereof with suitable co-solvents such as ethanol. Solution formulations also obviate physical stability problems associated with suspension formulations, thus assuring reproducible dosage. Furthermore, when a systemic effect is required, as in the case of the invention, aerosol solution formulations offer the advantage that much finer clouds, largely defined by the drug concentration in the solution, are generated and the finer clouds give more extensive deposition in the lung periphery.
  • ethanol When a medicament is very slightly soluble in the propellant large amounts of ethanol are required. A large amount of ethanol, in turn, increases, proportionally to its concentration, the size of the aerosol droplets leaving the actuator orifice. The larger size droplets extensively deposit into the oropharyngeal tract to the detriment of the drug dose fraction which penetrates into the lower airways (respirable fraction). A poorly respirable fraction is unlikely to give the medicament serum levels necessary to produce a therapeutic effect. Moreover, an increased amount of ethanol in the formulation means also an increased amount of residual water.
  • an amount of water up to 10% w/w, preferably comprised between 0.5 and 8% w/w and more preferably between 0.5 and 6% may be in some cases useful to improve the solubility of the medicament in the propellant/co-solvent system, in other cases the presence of water could enhance the degradation of the medicament and could be detrimental to the physical stability of the formulation giving rise to a non- homogeneous system. It would be advantageous to provide a formulation for pulmonary delivery to be used with pressurised metered dose inhalers, which is chemically and physically stable and capable of providing, on actuation, a suitable fine particle dose (FPD) and a fine respirable fraction (FPF) providing early therapeutic plasma levels of a medicament.
  • FPD fine particle dose
  • FPF fine respirable fraction
  • the fine particle dose or respirable dose is the amount of active particles of size less than 4.7 ⁇ m and the fine particle fraction or respirable fraction is the ratio between the respirable dose and the dose delivered on actuation of the inhaler.
  • the respirable fraction should be at least 30%, preferably more than 40%, even more preferably higher than 50% of the delivered dose. It would also be highly advantageous to provide formulation whose delivered dose is highly reproducible after repeated administrations from the pMDI.
  • the invention provides a solution to said problems by means of solution formulations comprising a medicament, an HFA propellant and optionally one or more co-solvents.
  • Said solutions are chemically stable for an adequate time and capable of providing, on actuation, a respirable fraction giving rise to onset-hastened therapeutic plasma levels of the medicament.
  • the preferred co-solvents are lower alkyl (C 1 -C 4 ) alcohols, polyols, polyalkylene glycols and their combinations.
  • Ethanol is particularly preferred.
  • co-solvents are (poly)alkoxy derivatives including polyalkoxy alcohols, in particular 2-(2-ethoxyethoxy) ethanol (available under the trademark Transcutol®).
  • polyalkoxy derivatives include polyoxyalkyl ethers and esters, such as poly oxy ethylene ethers or esters.
  • the preferred polyoxyethylene ethers and esters are polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters and polyoxyethylene stearates.
  • a fatty acid alkyl ester can be also utilised.
  • the preferred fatty acid alkyl esters are ethyl oleate, isopropyl myristate and isopropyl palmitate.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a medicament, a HFA propellant, an amount of ethanol up to 30%, preferably up to 20%, more preferably up to
  • 0.2% to 10% w/w preferably from 0.5 to 10% w/w, more preferably from 0.5 to 6% w/w, even more preferably from 1 to 2% w/w.
  • the polarity may be quantified, and thus compared, in terms of a dielectric constant, or by using Maxwell's equation to relate dielectric constant to the square of the refractive index - the refractive index of materials being readily measurable or obtainable from the literature.
  • the polarity of co-solvents may be measured using the Kauri- butanol value for estimation of solvent power.
  • the protocol is described in
  • Co-solvents with a higher polarity than ethanol can be preferably selected from lower alkyl (C ⁇ -C 4 ) alcohol, polyols or polyalkylene glycols.
  • the preferred polyols include propylene glycol and glycerol and the preferred polyalkylene glycol is polyethylene glycol.
  • the co-solvents with a higher polarity than ethanol water is to be considered comprised.
  • the amount of water, when present, is up to 10% w/w, preferably comprised between 0.5 and 8% w/w and more preferably between 0.5 and 6%.
  • the invention provides a pharmaceutical composition consisting essentially of a medicament, a HFA propellant, optionally ethanol in amounts comprised between 2 and 30% w/w, preferably between 5% and 20% w/w, more preferably up to 10% w/w and optionally a co-solvent.
  • the amount of the active ingredient is of at least 0.01% w/v and preferably comprised between 0.1 and 1.0% w/v.
  • ethanol preferably comprised around 5-8% w/w, more preferably around 5% w/w
  • ethanol helps the reduction of the amount of very small particles ( ⁇ 0.5 ⁇ m) which would be exhaled due to a short residency time in the lung.
  • ethanol reduces the deposition of discharged material on the inhaler actuator orifice, so improving the dose reproducibility after repeated administrations by keeping 'clean' the actuator orifice.
  • the formulation may optionally contain small amounts of additional components such as surfactants or other additives which are preservatives, buffers, antioxidants, radical quenchers, sweeteners and taste masking agents.
  • additional components such as surfactants or other additives which are preservatives, buffers, antioxidants, radical quenchers, sweeteners and taste masking agents.
  • the preferred organic surfactant is selected from oleyl alcohol, sorbitan trioleate, sorbitan mono-oleate, sorbitan monolaurate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan mono-oleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxy ethylene and oxypropylene, oleic acid, synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, isopropyl myristate, glyceryl mono- oleate, glyceryl monostearate, glyceryl monoricinoleate, cetyl alcohol, stearyl alcohol, cetyl pyridinium chloride, olive oil, glyceryl monolaurate, corn oil,
  • the invention provides a method of filling an aerosol inhaler with a composition of the invention, the method comprising:
  • any medicament which can be administered by inhalation as aerosol capable of being solubilized in an HFA/ethanol/co-solvent system and of being absorbed into the blood stream via the lung, may be used in the aerosol composition of the invention.
  • medicaments are cyclooxigenase-, mast cell-, lipoxigenase- and proteolytic enzyme - inhibitors, arachidonic acid-, leukotriene-, thromboxane-, sodium/potassium channel-, neurokinin-, tachykinin-, bradykinin-, muscarine-, histamine-, phosphodiesterase- and selectin - antagonists, potassium channel blockers, anti-infective agents, antibiotics, pentamidine, cytostatics, fungistatics, free- radical scavengers, vitamins, hormones, immunostimulants, immunosuppressants, heparin, antidiabetics, analgesics, hypnotics and the like, for example:
  • leukotriene antagonists such as iralukast, zafirlukast and pranlukast, - a lipoxygenase inhibitor such as zileuton,
  • - sodium channel antagonists such as amiloride, potassium channel antagonists, bimakalim,
  • - histamine receptor antagonists such as epinastine, azelastine, cinnarizine, cetrizine, mizolastine, mequitamium, chlorpheniramine, astemizole, terfenadine and fenoxfenadine,
  • antimigrain agents such as ergot alkaloids methisergide, ergotamine, serotonin, sumatriptan, zolmitriptan, cyclan delate etc.
  • - analgesics such as fentanyl, morphine, buprenorphine, opium, heroin, nalbuphine, pentazocine, oxycodone, tramadol, pethidine, tilidine, methadone, nefopam, dextropropoxyphene, piritramide, etc.
  • - antiemetics such as bromopride, domperidone, metoclopramide, triethylperazine, trifluoropromazine, meclozine, chlorphenoxamine, dimenhydrinate etc.
  • - antibiotics such as penicillins (e.g. azlocillin), cephalosporins (e.g. cefotiam or ceftriaxone), carbapenems, monobactams, aminoglycosides (e.g. streptomycin, neomycin, gentamycin, amikacin or tobramycin), quinolones (e.g. ciprofloxacin), macrolides (e.g.
  • erythromycin erythromycin
  • nitroimidazoles e.g. tinidazol
  • lincosamide e.g. clindamycin
  • glycopeptides e.g. vancomycin
  • polypeptides e.g. bacitracin
  • mupirocin e.g.
  • vitamins and free-radical scavengers such as vitamin A, B, C, D or E, catalase, superoxide dismutase, reduced glutathione etc.
  • antidiabetics such as glibenclamide, glipizide, gliclazide, glimepiride, troglitazone etc.
  • - hypnotics such as benzodiazepines, piperidonediones, antihistaminics etc., - neuroleptics, antidepressants and anticonvulsants such as benzodiazepines, phenothiazines, butyrophenones, sulpiride, hydantoins, barbiturates, succinimides, carbamazepine etc.,
  • - systemically active drugs such as, for example, isosorbide dinitrate, isosorbide mononitrate, apomorphine and cannabinoids, - antiinflammatory agents,
  • hormones and their synthetic analogues such as androgens (e.g. testosterone), antioestrogens, LHRH, leuprolide acetate, calcitonin, parathyrin, somatotropin, oxytocin, prolactin, glucagon, erythropoietin, atriopeptin, melanotropin, thyrotropin, gonadotropin, vasopressin, insulin, etc.
  • androgens e.g. testosterone
  • antioestrogens e.g. testosterone
  • LHRH leuprolide acetate
  • calcitonin parathyrin
  • somatotropin e.g. somatotropin
  • oxytocin prolactin
  • glucagon erythropoietin
  • erythropoietin atriopeptin
  • melanotropin thyrotropin
  • gonadotropin vasopressin
  • cytostatics such as nitrogen mustard derivatives (such as ifosphamide), N-Nitrosourea derivatives (e.g. lomustin), purine and pyrimidine bases antagonists (e.g. fluorouracil), platinum complexes (e.g. carboplatin), anthracyclines (e.g. doxorubicin), podophylline derivatives (e.g. podophyllotoxin).
  • nitrogen mustard derivatives such as ifosphamide
  • N-Nitrosourea derivatives e.g. lomustin
  • purine and pyrimidine bases antagonists e.g. fluorouracil
  • platinum complexes e.g. carboplatin
  • anthracyclines e.g. doxorubicin
  • podophylline derivatives e.g. podophyllotoxin
  • the aerosol solution formulations of the invention can be advantageously applied also to compounds already utilised in inhalation compositions, for instance a beta-mimetic such as salmeterol; a corticosteroid preferably selected from triamcinolone, ciclesonide, fluticasone and mometasone; an anticholinergic such as oxitropium bromide and tiotropium bromide; a mast cell inhibitor such as cromoglycic acid, nedocromil etc.
  • a beta-mimetic such as salmeterol
  • a corticosteroid preferably selected from triamcinolone, ciclesonide, fluticasone and mometasone
  • an anticholinergic such as oxitropium bromide and tiotropium bromide
  • a mast cell inhibitor such as cromoglycic acid, nedocromil etc.
  • the high efficiency cloud generation allows to prepare formulations containing a medicament with a reduced nominal dose and a larger percentage of clinically useful medicament deposition with respect to the reference composition (FPF of at least 30%, preferably higher than 40%, even more preferably more higher than 50% of the delivered dose) and with defined particle size targeting specific areas of the lungs.
  • Said medicaments can optionally be used in the form of their esters, isomers, enantiomers o racemates and, in the case of acids or bases, as such or in the form of their pharmaceutically acceptable salts.
  • the concentration of the active ingredient is at least 0.01% w/v, preferably at least 0.05% w/v, more preferably between 0.1% w/v and 1.0% w/v, even more preferably at least 1.0% w/v.
  • the formulation is suitable for delivering a therapeutic amount of the active ingredient in one or two actuations.
  • the formulation will be suitable for delivering a therapeutic dose of at least 25 ⁇ g/dose, preferably between 50 and 500 ⁇ g/dose.
  • therapeutic dose it is meant the amount of active ingredient delivered by a single actuation of the inhaler able to produce a pharmacodynamic effect.
  • the formulations of the invention could be filled into cans suitable for delivering pharmaceutical aerosol formulations. Certain medicaments are subject to enhanced chemical degradation when stored in contact with the standard metal container usually made of aluminium. In these cases the formulations will be filled preferably into cans having part or all of the internal surfaces made of anodised aluminium, stainless steel or lined with an inert organic coating.
  • Examples of preferred coatings are epoxy-phenol resins, perfluoroalkoxyalkane, perfluoroalkoxy alkylene, perfluoroalkylenes such as polytetrafluoro-ethylene, fluorinated-ethylene-propylene, polyether sulfone and a copolymer fluorinated-ethylene-propylene polyether sulfone.
  • Other suitable coatings could be polyamide, polyimide, polyamideimide, polyphenylene sulfide or their combinations.
  • cans having a rolled-in rim and preferably a part or full rollover rim are used.
  • the formulation is actuated by a metering valve capable of delivering a volume of between 25 ⁇ l and 100 ⁇ l.
  • the choice of the metering valve and type of gasket will be made according the knowledge of the person skilled in the art.
  • the gasket may comprise any suitable elastomeric material such as low density polyethylene, EPDM, chloroprene and TPE.
  • Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example from Nalois, France, Bespak pic, UK and 3M, ⁇ eotechnic Ltd, UK. For reasons of chemical stability of the medicament in solution, it is preferred in some cases that the internal surfaces of metal valve components in contact with the formulation are coated with an inert material.
  • valve actuators with orifice diameter from 0.20 to 0.50 mm can be generally used with the aerosol formulations of the invention.
  • valve actuators provided with orifice diameters comprised between 0.10-0.20 mm are advantageously used.
  • the hydrofluorocarbon propellant is preferably selected from the group of HFA 134a, HFA 227 and mixtures thereof.
  • the co-solvent may include one or more solvents and in this case their ratio is a critical factor for an efficient aerosolization.
  • the selection of said ratios may be anyhow made by the skilled in the art on the basis of the chemico-physical characteristics of the considered medicament.
  • the preferred co-solvents are usually alcohols such as ethanol, propanol, propylene glycol, polyethylene glycol, glycerol and their mixture in a total amount up to 30% w/w, preferably up to 25% w/w, more preferably up to 20% w/w.
  • alcohols such as ethanol, propanol, propylene glycol, polyethylene glycol, glycerol and their mixture in a total amount up to 30% w/w, preferably up to 25% w/w, more preferably up to 20% w/w.
  • Another useful co-solvent in some kinds of formulations is water.
  • the droplets size is between about 0.5 ⁇ m and 2.5 ⁇ m, corresponding to a MMAD of about 1-2 ⁇ m.
  • the assembly of the pMDI cans was carried out using hand operated crimping and filling equipment.
  • Formulations were prepared by accurately weighing the required quantity of drug into the can or vial. The appropriate volume of ethanol and the other co-solvent if required in the formulation, was then added.
  • the valve was crimped onto the vial/can and the assembled vial/can was ultra-sonicated for approximately 10 minutes.
  • the HFA propellant was filled through the valve and the pMDI was ultra-sonicated for a further 10 minutes. In the case of formulations that contained drug and propellant only the pMDI was ultra-sonicated once, after the propellant had been added.
  • Final compositions were calculated as percentage w/v for the active ingredient and as percentage w/w for the co-solvents.
  • MMAD values and corresponding geometric standard deviation (GSD) were calculated from plots of the cumulative percentage undersize of drug collected on each ACI plate (probit scale), against the upper cut off diameter for each respective ACI plate (log 10 scale).
  • the metered dose which is the sum of the dose delivered through the Andersen apparatus plus the active ingredient residue deposited on the device actuator; the cumulative amount of active particles deposited on the various ACI stages; the amount on the actuator; the amount in the adaptor and in the throat (adp/throat); the fine particle dose or respirable dose (FPD) which is the amount of particles deposited on stages 3 to filter of the ACI and corresponds to the amount of particles of size less than 4.7 ⁇ m; the fine particle fraction or respirable fraction which is the ratio between the respirable dose and the dose delivered ex-actuator.
  • formulations according to the invention comprise:
  • the formulation comprises up to 1% w/v diisobutyryl apomorphine, up to 5% w/w ethanol, from 0 to 0.1% w/w glycerol and HFA 134a,
  • the formulation comprises up to 0.26% w/v leuprolide acetate, from 15 to 30% w/w ethanol, from 2 to 5% w/w water and HFA 134a.
  • diisobutyryl apomorphine HFA 134a solution formulations containing 5% w/w ethanol and 0.1%) w/w glycerol were produced.
  • the cans were provided with actuators with an orifice diameter of 0.22 mm.
  • the diisobutyryl apomorphine formulations prepared according to the invention presented a MMAD of about 2.0 ⁇ m, a fine particle fraction (FPF) of at least 70-75%, whereas the amount of active particles of sizes included in the range from 0.43 to 3.3 ⁇ m was of at least of 60%.
  • FPF fine particle fraction
  • a stability study on a formulation prepared according to the Example 1 was initiated storing coated aluminum cans upright and inverted at 25°C.
  • the leuprolide acetate formulation prepared according to the invention presented a MMAD of about 1.0 ⁇ m, a fine particle fraction (FPF) of at least 72%), whereas the amount of active particles of sizes included in the range from 0.43 to 3.3 ⁇ m was of at least of 61%.
  • FPF fine particle fraction
  • HFA 134a solution formulation containing 0.08% w/v (80 ⁇ g/100 ⁇ l) leuprolide acetate, 18% w/w ethanol and 3% w/w water was produced.
  • the cans were provided with actuators with an orifice diameter of 0.14 mm.
  • the leuprolide acetate formulation prepared according to the invention presented a MMAD of about 1.3 ⁇ m, a fine particle fraction (FPF) of at least 59%, whereas the amount of active particles of sizes included in the range from 0.43 to 3.3 ⁇ m was of at least of 52%.
  • FPF fine particle fraction
  • the leuprolide acetate content was determined by HPLC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention discloses an aerosol pharmaceutical composition comprising a medicament in solution in a mixture of a hydrofluoroalkane propellant and one or more co-solvents wherein the aerosol liquid droplets delivered on actuation of the inhaler have a particle size comprised between 0,5 µm and 2.5 µm, with a mass median aerodynamic diameter of about 1-2 µm and wherein the fine particle fraction is at least 30%.

Description

AEROSOL FORMULATIONS FOR PULMONARY ADMINISTRATION OF MEDICAMENTS TO PRODUCE A SYSTEMIC EFFECT
Field of the invention
This invention relates to aerosol solution formulations comprising a medicament, a propellant, one or more co-solvents and optionally other additives commonly used in this kind of formulations. Background of the invention
Many pharmaceutically active compounds currently used in clinical practice and exhibiting problems of administration and/or absorption by the oral, parenteral or transdermal administration could take advantage from a pulmonary delivery, aimed at obtaining a systemic effect. Pharmaceutically active compounds could be administered to the respiratory tract by using pressurised metered dose inhalers (pMDIs). PMDIs use a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol.
The formulation can be a solution or a suspension. Solution formulations, in comparison to suspensions, do not present problems of physical stability of the suspended particles and could therefore guarantee a higher dose uniformity and reproducibility.
As far as the propellant is concerned, hydrofluoroalkanes [(HFAs) known also as hydro-fluoro-carbons (HFCs)] would be mandatory propellants as chlorofluorocarbons (known also as Freons or CFCs), which were for many years the preferred aerosol propellants for pharmaceutical use, have been banned in view of their environmental impact.
In particular, 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3- heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non-CFC propellants and a number of pharmaceutical aerosol formulations using such HFA propellants have been disclosed. Disclosure of the invention
The aim of providing solution formulations in a HFA propellant for aerosol delivery of medicaments is to give a prompt systemically active dose of said medicament via the respiratory tract.
Hereinafter the term medicament is used to define any pharmaceutical active compound which could take advantage from a pulmonary delivery so as to produce a systemic therapeutic effect.
In order to provide therapeutically useful plasma levels, a therapeutic concentration of medicament and an efficient aerosol delivery should be achieved.
An important parameter for an efficient aerosol delivery to produce a systemic therapeutic effect is the particle size distribution in the aerosol cloud.
When the formulation is in the form of suspension, the particle size of the cloud is dominated by the particle size of the suspended drug, defined by the milling/micronization process.
When the formulation is in the form of solution, the volumetric contribution of suspended drug particles is absent and much finer liquid droplets clouds, largely defined by the drug concentration in the solution, are generated.
The size of the particles provided by the pMDI, is normally expressed as mass median aerodynamic diameter (MMAD). The particle size of choice of aerosol medicaments for the treatment of bronchopulmonary diseases is usually of approximately 3 μm. The preferred diameter of the aerosol particles or droplets is comprised between 0.5 and 5 μm.
When the medicament is delivered to the lungs through an aerosol metered dose inhaler so as to produce a systemic effect, the particles should be small enough to be delivered to the lungs and to be absorbed into the bloodstream upon inhalation, i.e. of a size advantageously comprised between about 0.5 μm and 2.5 μm (MMAD of about 1-2 μm). Particles smaller than 0.5 μm are indeed not therapeutically useful as they are exhaled.
The aerosol solution formulations offer the advantage of being homogeneous with the active ingredient and with the excipients which are completely dissolved in the propellant vehicle or in the mixtures thereof with suitable co-solvents such as ethanol. Solution formulations also obviate physical stability problems associated with suspension formulations, thus assuring reproducible dosage. Furthermore, when a systemic effect is required, as in the case of the invention, aerosol solution formulations offer the advantage that much finer clouds, largely defined by the drug concentration in the solution, are generated and the finer clouds give more extensive deposition in the lung periphery.
When a medicament is slightly soluble in HFA propellants such as HFA 134a and HFA 227 or in their mixture, the use of a solvent, generally ethanol is necessary.
When a medicament is very slightly soluble in the propellant large amounts of ethanol are required. A large amount of ethanol, in turn, increases, proportionally to its concentration, the size of the aerosol droplets leaving the actuator orifice. The larger size droplets extensively deposit into the oropharyngeal tract to the detriment of the drug dose fraction which penetrates into the lower airways (respirable fraction). A poorly respirable fraction is unlikely to give the medicament serum levels necessary to produce a therapeutic effect. Moreover, an increased amount of ethanol in the formulation means also an increased amount of residual water. Whereas an amount of water up to 10% w/w, preferably comprised between 0.5 and 8% w/w and more preferably between 0.5 and 6% may be in some cases useful to improve the solubility of the medicament in the propellant/co-solvent system, in other cases the presence of water could enhance the degradation of the medicament and could be detrimental to the physical stability of the formulation giving rise to a non- homogeneous system. It would be advantageous to provide a formulation for pulmonary delivery to be used with pressurised metered dose inhalers, which is chemically and physically stable and capable of providing, on actuation, a suitable fine particle dose (FPD) and a fine respirable fraction (FPF) providing early therapeutic plasma levels of a medicament. The fine particle dose or respirable dose is the amount of active particles of size less than 4.7 μm and the fine particle fraction or respirable fraction is the ratio between the respirable dose and the dose delivered on actuation of the inhaler. The respirable fraction should be at least 30%, preferably more than 40%, even more preferably higher than 50% of the delivered dose. It would also be highly advantageous to provide formulation whose delivered dose is highly reproducible after repeated administrations from the pMDI.
Since a high systemic exposure of the aerosol particles would, in this case, be of benefit, it would be even more advantageous to provide a formulation wherein the composition of the whole solvent system has been adjusted in order to allow the generation of aerosol particles which could then allow a deep lung penetration, at the same time minimizing the amount of very small particles (<0.5 μm) which would be exhaled.
The invention provides a solution to said problems by means of solution formulations comprising a medicament, an HFA propellant and optionally one or more co-solvents. Said solutions are chemically stable for an adequate time and capable of providing, on actuation, a respirable fraction giving rise to onset-hastened therapeutic plasma levels of the medicament. The preferred co-solvents are lower alkyl (C1-C4) alcohols, polyols, polyalkylene glycols and their combinations.
Ethanol is particularly preferred.
Other suitable co-solvents are (poly)alkoxy derivatives including polyalkoxy alcohols, in particular 2-(2-ethoxyethoxy) ethanol (available under the trademark Transcutol®).
Further (poly)alkoxy derivatives include polyoxyalkyl ethers and esters, such as poly oxy ethylene ethers or esters. The preferred polyoxyethylene ethers and esters are polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters and polyoxyethylene stearates.
As a co-solvent a fatty acid alkyl ester can be also utilised. The preferred fatty acid alkyl esters are ethyl oleate, isopropyl myristate and isopropyl palmitate.
According to a preferred embodiment, the invention provides a pharmaceutical composition comprising a medicament, a HFA propellant, an amount of ethanol up to 30%, preferably up to 20%, more preferably up to
10% w/w and a co-solvent with a higher polarity than ethanol in amount from
0.2% to 10% w/w, preferably from 0.5 to 10% w/w, more preferably from 0.5 to 6% w/w, even more preferably from 1 to 2% w/w. The polarity may be quantified, and thus compared, in terms of a dielectric constant, or by using Maxwell's equation to relate dielectric constant to the square of the refractive index - the refractive index of materials being readily measurable or obtainable from the literature.
Alternatively, the polarity of co-solvents may be measured using the Kauri- butanol value for estimation of solvent power. The protocol is described in
ASTM Standard: Designation 1133-86.
The addition of a co-solvent with a higher polarity than ethanol allows reduction in the ethanol amount allowing the modulation of the particle size of the produced aerosol droplets.
Co-solvents with a higher polarity than ethanol can be preferably selected from lower alkyl (Cι-C4) alcohol, polyols or polyalkylene glycols.
The preferred polyols include propylene glycol and glycerol and the preferred polyalkylene glycol is polyethylene glycol.
Among the co-solvents with a higher polarity than ethanol water is to be considered comprised. The amount of water, when present, is up to 10% w/w, preferably comprised between 0.5 and 8% w/w and more preferably between 0.5 and 6%. According to an even more preferred embodiment, the invention provides a pharmaceutical composition consisting essentially of a medicament, a HFA propellant, optionally ethanol in amounts comprised between 2 and 30% w/w, preferably between 5% and 20% w/w, more preferably up to 10% w/w and optionally a co-solvent. Advantageously, the amount of the active ingredient is of at least 0.01% w/v and preferably comprised between 0.1 and 1.0% w/v.
Small amounts of ethanol and of a co-solvent are useful also when the medicament is fully soluble in the propellant.
It has been indeed found that, although the solvent is not needed to dissolve the medicament in the propellant, a small amount of ethanol (preferably comprised around 5-8% w/w, more preferably around 5% w/w), influencing the deposition characteristics, may make systemic delivery easier, since ethanol helps the reduction of the amount of very small particles (<0.5 μm) which would be exhaled due to a short residency time in the lung. Moreover, ethanol reduces the deposition of discharged material on the inhaler actuator orifice, so improving the dose reproducibility after repeated administrations by keeping 'clean' the actuator orifice.
Due to this "cleaning" effect of ethanol generally the use of surface active agents or "surfactants" as valve lubricants is not necessary.
In certain cases, however, the formulation may optionally contain small amounts of additional components such as surfactants or other additives which are preservatives, buffers, antioxidants, radical quenchers, sweeteners and taste masking agents.
The preferred organic surfactant is selected from oleyl alcohol, sorbitan trioleate, sorbitan mono-oleate, sorbitan monolaurate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan mono-oleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxy ethylene and oxypropylene, oleic acid, synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, isopropyl myristate, glyceryl mono- oleate, glyceryl monostearate, glyceryl monoricinoleate, cetyl alcohol, stearyl alcohol, cetyl pyridinium chloride, olive oil, glyceryl monolaurate, corn oil, cotton seed oil or sunflower seed oil.
According to a further aspect, the invention provides a method of filling an aerosol inhaler with a composition of the invention, the method comprising:
(a) weighing the required quantity of active ingredient into the can or vial;
(b) adding the appropriate volume of ethanol and of an additional co- solvent, if required;
(c) crimping with valves and gassing;
(d) adding a propellant containing a hydrofluoroalkane (HFA). Any medicament which can be administered by inhalation as aerosol, capable of being solubilized in an HFA/ethanol/co-solvent system and of being absorbed into the blood stream via the lung, may be used in the aerosol composition of the invention. Examples of said medicaments are cyclooxigenase-, mast cell-, lipoxigenase- and proteolytic enzyme - inhibitors, arachidonic acid-, leukotriene-, thromboxane-, sodium/potassium channel-, neurokinin-, tachykinin-, bradykinin-, muscarine-, histamine-, phosphodiesterase- and selectin - antagonists, potassium channel blockers, anti-infective agents, antibiotics, pentamidine, cytostatics, fungistatics, free- radical scavengers, vitamins, hormones, immunostimulants, immunosuppressants, heparin, antidiabetics, analgesics, hypnotics and the like, for example:
- leukotriene antagonists such as iralukast, zafirlukast and pranlukast, - a lipoxygenase inhibitor such as zileuton,
- sodium channel antagonists such as amiloride, potassium channel antagonists, bimakalim,
- arachidonic acid antagonists such as 2-benzoxazolamine,
- histamine receptor antagonists such as epinastine, azelastine, cinnarizine, cetrizine, mizolastine, mequitamium, chlorpheniramine, astemizole, terfenadine and fenoxfenadine,
- antimigrain agents such as ergot alkaloids methisergide, ergotamine, serotonin, sumatriptan, zolmitriptan, cyclan delate etc.,
- analgesics such as fentanyl, morphine, buprenorphine, opium, heroin, nalbuphine, pentazocine, oxycodone, tramadol, pethidine, tilidine, methadone, nefopam, dextropropoxyphene, piritramide, etc.,
- antiemetics such as bromopride, domperidone, metoclopramide, triethylperazine, trifluoropromazine, meclozine, chlorphenoxamine, dimenhydrinate etc., - antibiotics such as penicillins (e.g. azlocillin), cephalosporins (e.g. cefotiam or ceftriaxone), carbapenems, monobactams, aminoglycosides (e.g. streptomycin, neomycin, gentamycin, amikacin or tobramycin), quinolones (e.g. ciprofloxacin), macrolides (e.g. erythromycin), nitroimidazoles (e.g. tinidazol), lincosamide (e.g. clindamycin), glycopeptides (e.g. vancomycin), polypeptides (e.g. bacitracin), mupirocin etc.,
- vitamins and free-radical scavengers such as vitamin A, B, C, D or E, catalase, superoxide dismutase, reduced glutathione etc.,
- antidiabetics such as glibenclamide, glipizide, gliclazide, glimepiride, troglitazone etc.,
- hypnotics such as benzodiazepines, piperidonediones, antihistaminics etc., - neuroleptics, antidepressants and anticonvulsants such as benzodiazepines, phenothiazines, butyrophenones, sulpiride, hydantoins, barbiturates, succinimides, carbamazepine etc.,
- systemically active drugs such as, for example, isosorbide dinitrate, isosorbide mononitrate, apomorphine and cannabinoids, - antiinflammatory agents,
- hormones and their synthetic analogues such as androgens (e.g. testosterone), antioestrogens, LHRH, leuprolide acetate, calcitonin, parathyrin, somatotropin, oxytocin, prolactin, glucagon, erythropoietin, atriopeptin, melanotropin, thyrotropin, gonadotropin, vasopressin, insulin, etc.,
- potency agent such as alprostadil,
- cytostatics such as nitrogen mustard derivatives (such as ifosphamide), N-Nitrosourea derivatives (e.g. lomustin), purine and pyrimidine bases antagonists (e.g. fluorouracil), platinum complexes (e.g. carboplatin), anthracyclines (e.g. doxorubicin), podophylline derivatives (e.g. podophyllotoxin). Although the preferred medicaments of the invention are those usually ministered as a pulmonary aerosol, the aerosol solution formulations of the invention can be advantageously applied also to compounds already utilised in inhalation compositions, for instance a beta-mimetic such as salmeterol; a corticosteroid preferably selected from triamcinolone, ciclesonide, fluticasone and mometasone; an anticholinergic such as oxitropium bromide and tiotropium bromide; a mast cell inhibitor such as cromoglycic acid, nedocromil etc.
The high efficiency cloud generation allows to prepare formulations containing a medicament with a reduced nominal dose and a larger percentage of clinically useful medicament deposition with respect to the reference composition (FPF of at least 30%, preferably higher than 40%, even more preferably more higher than 50% of the delivered dose) and with defined particle size targeting specific areas of the lungs.
Said medicaments can optionally be used in the form of their esters, isomers, enantiomers o racemates and, in the case of acids or bases, as such or in the form of their pharmaceutically acceptable salts.
Advantageously, the concentration of the active ingredient is at least 0.01% w/v, preferably at least 0.05% w/v, more preferably between 0.1% w/v and 1.0% w/v, even more preferably at least 1.0% w/v.
It is preferable that the formulation is suitable for delivering a therapeutic amount of the active ingredient in one or two actuations. Advantageously the formulation will be suitable for delivering a therapeutic dose of at least 25 μg/dose, preferably between 50 and 500 μg/dose. By "therapeutic dose" it is meant the amount of active ingredient delivered by a single actuation of the inhaler able to produce a pharmacodynamic effect. The formulations of the invention could be filled into cans suitable for delivering pharmaceutical aerosol formulations. Certain medicaments are subject to enhanced chemical degradation when stored in contact with the standard metal container usually made of aluminium. In these cases the formulations will be filled preferably into cans having part or all of the internal surfaces made of anodised aluminium, stainless steel or lined with an inert organic coating. Examples of preferred coatings are epoxy-phenol resins, perfluoroalkoxyalkane, perfluoroalkoxy alkylene, perfluoroalkylenes such as polytetrafluoro-ethylene, fluorinated-ethylene-propylene, polyether sulfone and a copolymer fluorinated-ethylene-propylene polyether sulfone. Other suitable coatings could be polyamide, polyimide, polyamideimide, polyphenylene sulfide or their combinations.
To further improve the stability, cans having a rolled-in rim and preferably a part or full rollover rim are used.
The formulation is actuated by a metering valve capable of delivering a volume of between 25 μl and 100 μl.
The choice of the metering valve and type of gasket will be made according the knowledge of the person skilled in the art. The gasket may comprise any suitable elastomeric material such as low density polyethylene, EPDM, chloroprene and TPE.
Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example from Nalois, France, Bespak pic, UK and 3M, Νeotechnic Ltd, UK. For reasons of chemical stability of the medicament in solution, it is preferred in some cases that the internal surfaces of metal valve components in contact with the formulation are coated with an inert material.
The currently used valve actuators with orifice diameter from 0.20 to 0.50 mm (and in particular 0.22, 0.33, 0.42 and 0.45 mm) can be generally used with the aerosol formulations of the invention. When large amounts of ethanol are required to dissolve the medicament, so as to obtain aerosol clouds with an optimal respirable fraction, valve actuators provided with orifice diameters comprised between 0.10-0.20 mm (and in particular 0.12, 0.14, 0.16, 0.18 mm) are advantageously used.
These kinds of orifices can be prepared according to the EP application n° 01 130521.6 in the Applicant's name.
In some cases, in order to stabilise the medicament in solution, it would be necessary to provide aerosol solutions with a specific apparent pH, which can be determined by the skilled in the art according to WO 01/894080.
The hydrofluorocarbon propellant is preferably selected from the group of HFA 134a, HFA 227 and mixtures thereof.
The co-solvent may include one or more solvents and in this case their ratio is a critical factor for an efficient aerosolization. The selection of said ratios may be anyhow made by the skilled in the art on the basis of the chemico-physical characteristics of the considered medicament.
The preferred co-solvents are usually alcohols such as ethanol, propanol, propylene glycol, polyethylene glycol, glycerol and their mixture in a total amount up to 30% w/w, preferably up to 25% w/w, more preferably up to 20% w/w.
Another useful co-solvent in some kinds of formulations is water.
Advantageously, the droplets size is between about 0.5 μm and 2.5 μm, corresponding to a MMAD of about 1-2 μm. Preparation of HFA Solution pMDIs
The assembly of the pMDI cans was carried out using hand operated crimping and filling equipment. Formulations were prepared by accurately weighing the required quantity of drug into the can or vial. The appropriate volume of ethanol and the other co-solvent if required in the formulation, was then added. The valve was crimped onto the vial/can and the assembled vial/can was ultra-sonicated for approximately 10 minutes. The HFA propellant was filled through the valve and the pMDI was ultra-sonicated for a further 10 minutes. In the case of formulations that contained drug and propellant only the pMDI was ultra-sonicated once, after the propellant had been added. Final compositions were calculated as percentage w/v for the active ingredient and as percentage w/w for the co-solvents. Solubility Studies All solubility investigations were conducted in plastic coated glass pMDI vials fitted with continuous spray valves. Once produced the medicament-HFA solution pMDIs were stored in refrigerator at 4°C (± 0.1 °C). The pMDI vials were removed periodically and the vials assessed visually with the aid of a polarized light unit for crystal growth. Cascade Impaction Studies
All impaction studies were conducted with formulations contained in cut edge anodised aluminium cans fitted with 50 μl or 100 μl valves. The studies were carried out using an Andersen Cascade Impactor (ACI) fitted with a USP XXII metal throat entry port. The ACI was operated at a flow rate of 28.3 ± 2 1 min _1. The HFA solution formulations were discharged into the ACI through actuators having an orifice diameter from 0.14 to 0.45 mm. Deposition of the drug on each ACI plate was determined by high pressure liquid chromatography (HPLC).
MMAD values and corresponding geometric standard deviation (GSD) were calculated from plots of the cumulative percentage undersize of drug collected on each ACI plate (probit scale), against the upper cut off diameter for each respective ACI plate (log 10 scale).
The following parameters were determined: the metered dose, which is the sum of the dose delivered through the Andersen apparatus plus the active ingredient residue deposited on the device actuator; the cumulative amount of active particles deposited on the various ACI stages; the amount on the actuator; the amount in the adaptor and in the throat (adp/throat); the fine particle dose or respirable dose (FPD) which is the amount of particles deposited on stages 3 to filter of the ACI and corresponds to the amount of particles of size less than 4.7 μm; the fine particle fraction or respirable fraction which is the ratio between the respirable dose and the dose delivered ex-actuator. Examples of formulations according to the invention comprise:
- apomorphine esters in a HFA propellant selected from HFA 134a, HFA 227 and their mixtures and a co-solvent selected from an alcohol, a polyol and their mixtures. In a particular embodiment the formulation comprises up to 1% w/v diisobutyryl apomorphine, up to 5% w/w ethanol, from 0 to 0.1% w/w glycerol and HFA 134a,
- leuprolide acetate in a HFA propellant selected from HFA 134a, HFA 227 and their mixtures and a cosolvent selected from an alcohol, water and their mixtures. In a particular embodiment the formulation comprises up to 0.26% w/v leuprolide acetate, from 15 to 30% w/w ethanol, from 2 to 5% w/w water and HFA 134a.
Example 1
Solubility studies of diisobutyryl apomorphine, aerosol delivery characteristics and stability of its corresponding pMDI formulations Solubility studies The solubility of diisobutyryl apomorphine was investigated by producing pMDI formulations at various percentages of ethanol in HFA 134a or in HFA 227.
The results showed that formulations containing up to 1% w/v diisobutyryl apomorphine are soluble in HFA 134a or HFA 227. Aerosol delivery characteristics studies
0.5% and 1% w/v (250 μg or 500 μg/50 μl respectively) diisobutyryl apomorphine HFA 134a solution formulations containing 5% w/w ethanol and 0.1%) w/w glycerol were produced. The cans were provided with actuators with an orifice diameter of 0.22 mm.
Two ACI deposition determinations were performed with each formulation. Twenty shots were discharged into the ACI.
The diisobutyryl apomorphine formulations prepared according to the invention presented a MMAD of about 2.0 μm, a fine particle fraction (FPF) of at least 70-75%, whereas the amount of active particles of sizes included in the range from 0.43 to 3.3 μm was of at least of 60%.
Stability study
A stability study on a formulation prepared according to the Example 1 was initiated storing coated aluminum cans upright and inverted at 25°C.
The recovery of diisobutyryl apomorphine was determined by HPLC.
At six months evaluation the recovery of the active ingredient was excellent and minimal degradation occurred. There was no significant difference between those cans stored upright and inverted. Example 2
Solubility studies of leuprolide acetate, aerosol delivery characteristics and stability of its corresponding pMDI formulations
Solubility studies
The solubility of leuprolide acetate was investigated by producing pMDI formulations at various percentages of ethanol and water in HFA 134a or in HFA 227.
The results showed that formulations containing up to 0.26% w/v leuprolide acetate are soluble in ethanol, water, HFA 134a systems.
When water was added a significant increase of leuprolide acetate solubility within ethanol/HFA 134a systems was obtained.
Aerosol delivery characteristics studies
0.04% w/v (40 μg/100 μl) leuprolide acetate HFA 134a solution formulation containing 15% w/w ethanol and 2% w/w water was produced. The cans were provided with actuators with an orifice diameter of 0.14 mm.
Two ACI deposition determinations were performed with the formulation. Ten shots were discharged into the ACI.
The leuprolide acetate formulation prepared according to the invention presented a MMAD of about 1.0 μm, a fine particle fraction (FPF) of at least 72%), whereas the amount of active particles of sizes included in the range from 0.43 to 3.3 μm was of at least of 61%.
Another HFA 134a solution formulation containing 0.08% w/v (80 μg/100 μl) leuprolide acetate, 18% w/w ethanol and 3% w/w water was produced. The cans were provided with actuators with an orifice diameter of 0.14 mm.
Two ACI deposition determinations were performed with the formulation. Ten shots were discharged into the ACI.
The leuprolide acetate formulation prepared according to the invention presented a MMAD of about 1.3 μm, a fine particle fraction (FPF) of at least 59%, whereas the amount of active particles of sizes included in the range from 0.43 to 3.3 μm was of at least of 52%.
Stability Studies
Stability studies on leuprolide 100 μg/50 μl HFA 134a pMDIs containing 30% w/w ethanol and 5% w/w water was initiated storing coated aluminum cans upright and inverted at 25°C.
The leuprolide acetate content was determined by HPLC.
Excellent stability was observed over the six-month stability study.

Claims

1. An aerosol pharmaceutical composition comprising a medicament solution in a mixture of a hydrofluoroalkane propellant and one or more co- solvents wherein the aerosol liquid droplets delivered on actuation of the inhaler have a particle size comprised between 0.5 μm and 2.5 μm, with a mass median aerodynamic diameter of about 1-2 μm and wherein the fine particle fraction is at least 30%.
2. A pharmaceutical formulation according to claim 1 characterized in that the concentration of the medicament is at least 0.01 w/v.
3. A pharmaceutical formulation according to claim 1 to 2, characterized in that the concentration of the medicament is at least 0.05% w/w.
4. A pharmaceutical formulation according to claims 1-3, wherein the propellant includes one or more HFAs selected from HFA 134a and HFA 227.
5. A pharmaceutical formulation according to claims 1-4, wherein the co- solvent is ethanol in an amount up to 30% w/w.
6. A pharmaceutical formulation according to claims 1-5, wherein the co- solvent is selected from ethanol, a lower alkyl (C1-C4) alcohol, a polyol or a polyalkylene glycol and their combinations.
7. A pharmaceutical formulation according to claim 6 wherein polyols are selected from glycerol and propylene glycol and the polyalkylene glycol is polyethylene glycol.
8. A pharmaceutical formulation according to claims 1-5, wherein the co- solvent is a (poly)alkoxy derivative selected from polyalkoxy alcohols and polyoxyalkyl ethers and esters.
9. A pharmaceutical formulation according to claim 8, wherein the polyalkoxy alcohol is Transcutol®.
10. A pharmaceutical formulation according to claim 8, wherein the polyoxyalkyl ethers and esters are selected from polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters and polyoxyethylene stearates.
11. A pharmaceutical formulation according to claims 1-5, wherein the co- solvent comprises a fatty acid alkyl ester selected from ethyl oleate, isopropyl myristate and isopropyl palmitate.
12. A pharmaceutical formulation according to claims 1-6 wherein the co- solvent comprises up to 10% w/w of water.
13. A pharmaceutical formulation according to any preceding claim, wherein the fine particle fraction is at least 40%.
14. A pharmaceutical formulation according to any preceding claim, wherein the fine particle fraction is at least 50%.
15. An aerosol inhaler containing a formulation as claimed in any of claims
1 to 14, wherein the valve actuator has an orifice diameter from 0.20 to 0.50 mm.
16. An aerosol inhaler containing a formulation as claimed in any of claims
1 to 14, wherein the valve actuator has an orifice diameter from 0.10 to 0.20 mm.
PCT/EP2003/001962 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect WO2003074023A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP03743339A EP1480616B1 (en) 2002-03-01 2003-02-26 Aerosol formulations of diisobutyryl apomorphine
AU2003215597A AU2003215597B2 (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
KR10-2004-7012649A KR20040091050A (en) 2002-03-01 2003-02-26 Aerosol Formalations for Pulmonary Administration of Medicaments to produce a Systemic Effect
JP2003572543A JP2005519094A (en) 2002-03-01 2003-02-26 Aerosol composition for pulmonary administration of drugs to produce systemic effects
US10/505,679 US20050129621A1 (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
AT03743339T ATE488224T1 (en) 2002-03-01 2003-02-26 AEROSOL FORMULATIONS OF DIISOBUTYRYL APOMORPHINE
DE60334973T DE60334973D1 (en) 2002-03-01 2003-02-26 Aerosol formulations of diisobutyryl apomorphine
EA200401006A EA008571B1 (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
BR0303348-1A BR0303348A (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary drug delivery to produce systemic effect
IL16384203A IL163842A0 (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
NZ535019A NZ535019A (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
CA2477879A CA2477879C (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
MXPA04008370A MXPA04008370A (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect.
NO20034874A NO20034874L (en) 2002-03-01 2003-10-31 Aerosol formulations for pulmonary administration of drugs to produce a systemic effect
TNP2004000148A TNSN04148A1 (en) 2002-03-01 2004-08-06 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
HRP20040751 HRP20040751A2 (en) 2002-03-01 2004-08-20 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (en) 2002-03-01 2002-03-01 Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP02004786.6 2002-03-01

Publications (1)

Publication Number Publication Date
WO2003074023A1 true WO2003074023A1 (en) 2003-09-12

Family

ID=27675679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001962 WO2003074023A1 (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect

Country Status (27)

Country Link
US (1) US20050129621A1 (en)
EP (2) EP1340492A1 (en)
JP (1) JP2005519094A (en)
KR (1) KR20040091050A (en)
CN (2) CN1638731A (en)
AR (2) AR038643A1 (en)
AT (1) ATE488224T1 (en)
AU (1) AU2003215597B2 (en)
BR (1) BR0303348A (en)
CA (1) CA2477879C (en)
DE (1) DE60334973D1 (en)
EA (1) EA008571B1 (en)
ES (1) ES2358293T3 (en)
GE (1) GEP20063985B (en)
HR (1) HRP20040751A2 (en)
IL (1) IL163842A0 (en)
MA (1) MA27107A1 (en)
MX (1) MXPA04008370A (en)
NO (1) NO20034874L (en)
NZ (1) NZ535019A (en)
PE (1) PE20030949A1 (en)
PL (1) PL372261A1 (en)
TN (1) TNSN04148A1 (en)
TW (1) TW200304833A (en)
UA (2) UA81238C2 (en)
WO (1) WO2003074023A1 (en)
ZA (3) ZA200406919B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505831A (en) * 2003-09-15 2007-03-15 ベクトゥラ・リミテッド Pharmaceutical composition for treating premature ejaculation by pulmonary inhalation
WO2012039741A1 (en) 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Novel block copolymer and micelle compositions and methods of use thereof

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (en) * 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
IT1303788B1 (en) * 1998-11-25 2001-02-23 Chiesi Farma Spa MEDICINAL AEROSOL FORMULATIONS.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (en) * 2000-01-07 2003-07-15 Chiesi Farma Spa DEVICE FOR THE ADMINISTRATION OF AEROSOL DOSED PRESSURIZED INPROPELLENT HYDROFLUOROALKANS.
IT1318514B1 (en) * 2000-05-12 2003-08-27 Chiesi Farma Spa FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
SK286694B6 (en) * 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosol pharmaceutical composition
ES2222294T3 (en) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. OPTIMIZED FORMULATION OF TOBRAMYCIN FOR ADMINISTRATION IN THE FORM OF AEROSOL.
PT3494995T (en) * 2002-03-01 2020-03-30 Chiesi Farm Spa Formoterol superfine formulation
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
GB0311701D0 (en) * 2003-05-21 2003-06-25 Karib Kemi Pharm Liited Improved metered dose inhaler product
KR20070000476A (en) * 2004-02-27 2007-01-02 키에시 파르마슈티시 엣스. 피. 에이. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
JP5209963B2 (en) * 2004-07-02 2013-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Aerosol suspension formulation containing TG227EA or TG134A as propellant
WO2007034207A2 (en) * 2005-09-25 2007-03-29 Cipla Limited Troventol formulation
US20070243262A1 (en) * 2005-12-21 2007-10-18 Hurley Kevin P Stable S-nitrosothiol formulations
DE102006017320A1 (en) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
EP2011534A1 (en) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Metered dose inhaler actuator
PE20090907A1 (en) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int NEW POWDER DRUGS CONTAINING THOTROPE AND SALMETEROL, AS WELL AS LACTOSE AS AN EXCIPIENT
US8551534B2 (en) 2007-10-10 2013-10-08 Parion Sciences, Inc. Inhaled hypertonic saline delivered by a heated nasal cannula
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
BR112013000921A2 (en) * 2010-07-12 2016-05-17 Xellia Pharmaceuticals Aps treatment of pulmonary infections by aerosolized administration of tobramycin
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
JP6219271B2 (en) 2011-06-07 2017-10-25 パリオン・サイエンシィズ・インコーポレーテッド Method of treatment
CA2859209A1 (en) * 2011-12-20 2013-06-27 Map Pharmaceuticals, Inc. Excipient-free aerosol formulation
GB201402513D0 (en) * 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
CA2952934A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
EP3297710A4 (en) * 2015-05-21 2019-05-01 Island Breeze Systems Ca, LLC Propellant based metered dose inhaler and food applicators and applicators
US11129848B2 (en) 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024420A1 (en) * 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
WO2000030608A1 (en) * 1998-11-25 2000-06-02 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (mdi)
GB2354007A (en) * 1999-09-11 2001-03-14 Glaxo Group Ltd A Fluticasone Propionate-Aerosol Composition
WO2001049350A1 (en) * 2000-01-07 2001-07-12 Chiesi Farmaceutici S.P.A. Aerosol inhaler
WO2001062227A2 (en) * 2000-02-22 2001-08-30 Chiesi Farmaceutici S.P.A. Anticholinergic drug formulations for treatment of chronic obstr uctive pulmonary disease
WO2001066089A2 (en) * 2000-03-09 2001-09-13 Gw Pharma Limited Pharmaceutical compositions comprising cannabis
WO2001074358A1 (en) * 2000-03-20 2001-10-11 Tap Pharmaceutical Products Inc. Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
IT1303788B1 (en) * 1998-11-25 2001-02-23 Chiesi Farma Spa MEDICINAL AEROSOL FORMULATIONS.
IT1318514B1 (en) * 2000-05-12 2003-08-27 Chiesi Farma Spa FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES.
SK286694B6 (en) * 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosol pharmaceutical composition
PT3494995T (en) * 2002-03-01 2020-03-30 Chiesi Farm Spa Formoterol superfine formulation
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024420A1 (en) * 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
WO2000030608A1 (en) * 1998-11-25 2000-06-02 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (mdi)
GB2354007A (en) * 1999-09-11 2001-03-14 Glaxo Group Ltd A Fluticasone Propionate-Aerosol Composition
WO2001049350A1 (en) * 2000-01-07 2001-07-12 Chiesi Farmaceutici S.P.A. Aerosol inhaler
WO2001062227A2 (en) * 2000-02-22 2001-08-30 Chiesi Farmaceutici S.P.A. Anticholinergic drug formulations for treatment of chronic obstr uctive pulmonary disease
WO2001066089A2 (en) * 2000-03-09 2001-09-13 Gw Pharma Limited Pharmaceutical compositions comprising cannabis
WO2001074358A1 (en) * 2000-03-20 2001-10-11 Tap Pharmaceutical Products Inc. Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505831A (en) * 2003-09-15 2007-03-15 ベクトゥラ・リミテッド Pharmaceutical composition for treating premature ejaculation by pulmonary inhalation
WO2012039741A1 (en) 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Novel block copolymer and micelle compositions and methods of use thereof

Also Published As

Publication number Publication date
ES2358293T3 (en) 2011-05-09
EP1480616A1 (en) 2004-12-01
EA200401006A1 (en) 2005-04-28
US20050129621A1 (en) 2005-06-16
ZA200406919B (en) 2006-06-28
DE60334973D1 (en) 2010-12-30
IL163842A0 (en) 2005-12-18
GEP20063985B (en) 2006-12-11
NO20034874L (en) 2003-12-23
UA81238C2 (en) 2007-12-25
ZA200406917B (en) 2006-06-28
BR0303348A (en) 2004-07-13
CN101502500A (en) 2009-08-12
AU2003215597B2 (en) 2008-07-31
CA2477879C (en) 2011-05-03
ZA200406918B (en) 2006-06-28
AR101593A2 (en) 2016-12-28
EP1480616B1 (en) 2010-11-17
HRP20040751A2 (en) 2004-12-31
NO20034874D0 (en) 2003-10-31
UA80695C2 (en) 2007-10-25
AR038643A1 (en) 2005-01-19
TW200304833A (en) 2003-10-16
CN1638731A (en) 2005-07-13
MA27107A1 (en) 2004-12-20
KR20040091050A (en) 2004-10-27
EA008571B1 (en) 2007-06-29
EP1340492A1 (en) 2003-09-03
TNSN04148A1 (en) 2007-03-12
NZ535019A (en) 2006-09-29
PL372261A1 (en) 2005-07-11
MXPA04008370A (en) 2004-11-26
PE20030949A1 (en) 2004-01-02
ATE488224T1 (en) 2010-12-15
CA2477879A1 (en) 2003-09-12
JP2005519094A (en) 2005-06-30
AU2003215597A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
CA2477879C (en) Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US6585958B1 (en) Medicinal aerosol formulations
US6461591B1 (en) Medical aerosol formulations
KR100961603B1 (en) Pressurized metered dose inhalers containing solutions of ?-2 agonists
KR101311662B1 (en) Pharmaceutical solution formulations for pressurized metered dose inhalers
US6193954B1 (en) Formulations for pulmonary delivery of dopamine agonists
EP1415647A1 (en) &#34;Long-acting beta-2 agonists ultrafine formulations&#34;
EP1480651B1 (en) Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020047012649

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P20040751A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 1-2004-501298

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/008370

Country of ref document: MX

ENP Entry into the national phase

Ref country code: GE

Ref document number: GE P

WWE Wipo information: entry into national phase

Ref document number: 372261

Country of ref document: PL

Ref document number: 2004/06917

Country of ref document: ZA

Ref document number: 8390

Country of ref document: GE

Ref document number: 163842

Country of ref document: IL

Ref document number: 2003215597

Country of ref document: AU

Ref document number: 535019

Country of ref document: NZ

Ref document number: 20038049775

Country of ref document: CN

Ref document number: 2477879

Country of ref document: CA

Ref document number: 2003572543

Country of ref document: JP

Ref document number: 200406917

Country of ref document: ZA

Ref document number: 200401006

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2003743339

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003743339

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10505679

Country of ref document: US